乌司奴单抗与维得利珠单抗在130例抗TNF难治性克罗恩病患者治疗一年后的比较有效性
该研究比较乌司奴单抗与维得利珠单抗在抗TNF难治性克罗恩病患者中12个月内的有效性。纳入85例使用维得利珠单抗和45例使用乌司奴单抗的患者,主要结局为诱导结束时(2个月)和12个月时无激素缓解率的差异。校正混杂因素后,乌司奴单抗组2个月无激素缓解率更高(OR 2.79,95%CI 1.06-7.39,P=0.038),12个月时无激素缓解率(OR 2.01,95%CI 0.89-4.56,P=0.095)未达统计学显著;乌司奴单抗组12个月治疗持续率更高(84.4% vs 61.5%,P=0.007)。
要点
- 抗TNF难治性克罗恩病患者中,乌司奴单抗组2个月无激素缓解率显著高于维得利珠单抗组(OR 2.79,95%CI 1.06-7.39,P=0.038)。
- 12个月无激素缓解率乌司奴单抗组OR 2.01(95%CI 0.89-4.56,P=0.095),未达统计学显著。
- 乌司奴单抗组12个月治疗持续率84.4% vs 维得利珠单抗组61.5%(P=0.007)。
核心结论
- 乌司奴单抗在治疗抗TNF难治性克罗恩病中似乎更有效,且更多患者坚持治疗。
研究设计与样本
- 纳入开始使用乌司奴单抗或维得利珠单抗治疗抗TNF难治性克罗恩病且随访至少12个月的患者,共130例(维得利珠单抗85例,乌司奴单抗45例)。
- 主要结局为诱导结束时(2个月)和12个月时无激素缓解率的差异,并评估临床应答、缓解、治疗持续、手术和不良事件发生率。
- 采用logistic回归分析评估与无激素缓解及临床应答和缓解相关的因素。
主要发现
- 在未校正模型中,乌司奴单抗治疗患者的无激素缓解率和临床缓解率显著更高。
- 校正混杂因素后,乌司奴单抗组2个月无激素缓解率更高(OR 2.79,95%CI 1.06-7.39,P=0.038)。
- 校正混杂因素后,乌司奴单抗组12个月无激素缓解率OR 2.01(95%CI 0.89-4.56,P=0.095)。
- 乌司奴单抗组12个月治疗持续率84.4% vs 维得利珠单抗组61.5%(P=0.007)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease but some patients lose response and require alternative biologic therapy. There are few data on comparative effectiveness of vedolizumab and ustekinumab in this setting. AIM: To compare the effectiveness of ustekinumab and vedolizumab in anti-TNF-refractory Crohn's disease over 12 months. METHODS: Patients commencing ustekinumab or vedolizumab for anti-TNF-refractory Crohn's disease with minimum follow-up of 12 months were included. The primary outcome measure was the difference in steroid-free remission rates at end of induction (2 months) and at 12 months. We also assessed rates of clinical response and remission, treatment persistence, surgery and adverse events in both groups. We performed logistic regression analysis to assess factors associated with steroid-free remission and clinical response and remission. RESULTS: We included 85 patients commencing vedolizumab and 45 commencing ustekinumab. In an unadjusted model, rates of steroid-free and clinical remission were significantly higher among ustekinumab-treated patients. After adjusting for confounders, steroid-free remission was higher among ustekinumab-treated patients at 2 months (odds ratio, OR 2.79, 95% confidence interval, CI 1.06-7.39, P = 0.038) and 12 months (OR 2.01, 95% CI 0.89-4.56, P = 0.095). More patients treated with ustekinumab remained on therapy at the end of 12 months (84.4% vs 61.5%, P = 0.007). CONCLUSIONS: Ustekinumab appeared more effective in treating anti-TNF-refractory Crohn's disease and more patients persisted with therapy.
引用
- Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 32955122. doi:10.1111/apt.16057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。